BPC-157 has shown promise for promoting healing in musculoskeletal injuries such as fractures, tendon ruptures, ligament tears, and muscle injuries, and plays a role in promoting cell growth, cell tissue regeneration, and collagen synthesis
WADA's rationale is that BPC-157 is a pharmacological substance not approved for human therapeutic use by any regulatory authority, and its tissue repair properties could provide a performance-enhancing benefit
Follow-up lasted for three months
Endogenous regulation Exogenous peptides can in principle trigger downregulation of endogenous production through feedback mechanisms, as is well documented with hormonal therapies
Rare side effects Increased appetite: Paradoxical for a fat loss peptide, but some users report increased hunger